These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
315 related articles for article (PubMed ID: 23026611)
21. Liver transplantation in patients with hepatocellular carcinoma: a single-center experience. Azzam AZ; Hegab B; Khalaf H; Al Bahili H; Mohammed H; Kamel Y; Abaalkhail F; Al-hamoudi W; Al Sofayan M; Al Sebayel M Exp Clin Transplant; 2011 Oct; 9(5):323-8. PubMed ID: 21967259 [TBL] [Abstract][Full Text] [Related]
22. Hepatocellular carcinoma in children and effect of living-donor liver transplantation on outcome. Arikan C; Kilic M; Nart D; Ozgenc F; Ozkan T; Tokat Y; Yagci RV; Aydogdu S Pediatr Transplant; 2006 Feb; 10(1):42-7. PubMed ID: 16499586 [TBL] [Abstract][Full Text] [Related]
23. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Vakili K; Pomposelli JJ; Cheah YL; Akoad M; Lewis WD; Khettry U; Gordon F; Khwaja K; Jenkins R; Pomfret EA Liver Transpl; 2009 Dec; 15(12):1861-6. PubMed ID: 19938113 [TBL] [Abstract][Full Text] [Related]
24. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Decaens T; Roudot-Thoraval F; Badran H; Wolf P; Durand F; Adam R; Boillot O; Vanlemmens C; Gugenheim J; Dharancy S; Bernard PH; Boudjema K; Calmus Y; Hardwigsen J; Ducerf C; Pageaux GP; Hilleret MN; Chazouillères O; Cherqui D; Mallat A; Duvoux C Liver Int; 2011 Jul; 31(6):792-801. PubMed ID: 21645209 [TBL] [Abstract][Full Text] [Related]
25. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM; Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643 [TBL] [Abstract][Full Text] [Related]
26. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Yao FY; Bass NM; Ascher NL; Roberts JP Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253 [TBL] [Abstract][Full Text] [Related]
28. Effect of steatosis donor liver transplantation on hepatocellular carcinoma recurrence: experience at a single institution. Teng da H; Zhu ZJ; Zheng H; Deng YL; Sun LY; Pan C; Liu YH; Song HL; Shen ZY Hepatogastroenterology; 2012 May; 59(115):858-62. PubMed ID: 22389257 [TBL] [Abstract][Full Text] [Related]
29. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liang W; Wu L; Ling X; Schroder PM; Ju W; Wang D; Shang Y; Kong Y; Guo Z; He X Liver Transpl; 2012 Oct; 18(10):1226-36. PubMed ID: 22685095 [TBL] [Abstract][Full Text] [Related]
30. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil. Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144 [TBL] [Abstract][Full Text] [Related]
31. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Tamura S; Kato T; Berho M; Misiakos EP; O'Brien C; Reddy KR; Nery JR; Burke GW; Schiff ER; Miller J; Tzakis AG Arch Surg; 2001 Jan; 136(1):25-30; discussion 31. PubMed ID: 11146770 [TBL] [Abstract][Full Text] [Related]
32. Prospective study on the outcome of patients with hepatocellular carcinoma registered for living donor liver transplantation: how long can they wait? Mizuno S; Yokoi H; Shiraki K; Usui M; Sakurai H; Tabata M; Sugimoto K; Takei Y; Yamakado K; Takeda K; Uemoto S; Isaji S Transplantation; 2010 Mar; 89(6):650-4. PubMed ID: 20048691 [TBL] [Abstract][Full Text] [Related]
33. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma. Abdel-Wahab M; Sultan AM; Fathy OM; Salah T; Elshobary MM; Elghawalby NA; Yassen AM; Elsarraf WM; Elsaadany MF; Zalatah K Hepatogastroenterology; 2013; 60(128):1847-53. PubMed ID: 24719918 [TBL] [Abstract][Full Text] [Related]
34. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio. Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512 [TBL] [Abstract][Full Text] [Related]
35. Hepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteria. Felga G; Evangelista AS; Salvalaggio PR; Curvelo LA; Della Guardia B; Almeida MD; Afonso RC; Ferraz-Neto BH Transplant Proc; 2012 Oct; 44(8):2459-61. PubMed ID: 23026620 [TBL] [Abstract][Full Text] [Related]
36. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852 [TBL] [Abstract][Full Text] [Related]
37. Comparative study of living and deceased donor liver transplantation as a treatment for hepatocellular carcinoma. Ninomiya M; Shirabe K; Facciuto ME; Schwartz ME; Florman SS; Yoshizumi T; Harimoto N; Ikegami T; Uchiyama H; Maehara Y J Am Coll Surg; 2015 Mar; 220(3):297-304.e3. PubMed ID: 25617912 [TBL] [Abstract][Full Text] [Related]
38. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation. Saab S; Yeganeh M; Nguyen K; Durazo F; Han S; Yersiz H; Farmer DG; Goldstein LI; Tong MJ; Busuttil RW Liver Transpl; 2009 Nov; 15(11):1525-34. PubMed ID: 19877207 [TBL] [Abstract][Full Text] [Related]